Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a “sandwich” protocol in patients with advanced endometrial cancer: a single-institution experience

Bibliography

• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC, Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11
   PubMed Web of Science ®Google Scholar
• Papanikolaou A, Kalogiannidis I, Goutzioulis M, Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 2006;274:91-6
   PubMedGoogle Scholar
• Onda T, Yoshikawa H, Mizutani K, Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997;75:1836-41
   PubMed Web of Science ®Google Scholar
• Mariani A, Webb MJ, Keeney GL, Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol 2002;87:112-17
   PubMed Web of Science ®Google Scholar
• Van Wijk FH, Huikeshoven FJ, Abdulkadir L, Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer 2006;16:1648-55
   PubMed Web of Science ®Google Scholar
• Stewart KD, Martinez AA, Weiner S, Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys 2002;54:527-35
   PubMedGoogle Scholar
• Sutton G, Axelrod JH, Bundy BN, Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;97:755-63
   PubMed Web of Science ®Google Scholar
• Mundt AJ, Murphy KT, Rotmensch J, Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1154-60
   PubMedGoogle Scholar
• Randall ME, Filiaci VL, Muss H, Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44
   PubMed Web of Science ®Google Scholar
• Van Wijk FH, van der Burg ME, Burger CW, Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009;19:431-46
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Swenerton KD, Pike JA, Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19:4048-53
   PubMed Web of Science ®Google Scholar
• Alvarez Secord A, Havrilesky LJ, Bae-Jump V, The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007;107:285-91
   PubMed Web of Science ®Google Scholar
• Secord AA, Havrilesky LJ, O'Malley DM, A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009;114:442-7
   PubMed Web of Science ®Google Scholar
• Geller MA, Ivy JJ, Ghebre R, A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011;121:112-17
   PubMed Web of Science ®Google Scholar
• Fields AL, Einstein MH, Novetsky AP, Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2008;108:201-6
   PubMed Web of Science ®Google Scholar
• Lupe K, D'Souza DP, Kwon JS, Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol 2009;114:94-8
   PubMed Web of Science ®Google Scholar
• Geller MA, Ivy J, Dusenbery KE, A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high-risk endometrial carcinoma. Gynecol Oncol 2010;118:19-23
   PubMedGoogle Scholar
• Fleming GF, Brunetto VL, Cella D, Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66
   PubMed Web of Science ®Google Scholar
• Gerszten K, Faul C, Huang Q. Pathologic stage III endometrial cancer treated with adjuvant radiation therapy. Int J Gynecol Cancer 1999;9:243-6
   PubMedGoogle Scholar
• Wong FC, Pang CP, Tang SK, Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement. Clin Oncol (R Coll Radiol) 2004;16:350-5
   PubMedGoogle Scholar
• McMeekin DS, Lashbrook D, Gold M, Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol 2001;81:273-8
   PubMedGoogle Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE version 4.0), published May 28, 2009. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/
   Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S105-43
   PubMedGoogle Scholar
• Buda A, Fossati R, Colombo N, Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005;23:4137-45
   PubMed Web of Science ®Google Scholar
• Park DC, Kim JH, Lew YO, Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004;92:59-63
   PubMed Web of Science ®Google Scholar
• Katsumata N, Noda K, Nozawa S, Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer 2005;93:999-1004
   PubMed Web of Science ®Google Scholar
• Gunthert AR, Ackermann S, Beckmann MW, Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol 2007;104:86-90
   PubMedGoogle Scholar
• Nomura H, Aoki D, Takahashi F, Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group Study (JGOG2041). Ann Oncol 2011;22:636-42
   PubMed Web of Science ®Google Scholar
• Connell PP, Rotmensch J, Waggoner S, The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999;74:74-9
   PubMedGoogle Scholar
• Mariani A, Webb MJ, Keeney GL, Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 2002;86:38-44
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Cragun JM, Calingaert B, The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007;104:401-5
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Secord AA, O'Malley DM, Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecol Oncol 2009;114:279-83
   PubMedGoogle Scholar